Cargando…

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells

Interferons (IFNs) have been tested for the therapeutic effects in various types of malignancy, but mechanisms of the anti-tumors effects and the differential biological activities among IFN members are dependent on respective cell types. In this study, we examined growth inhibitory activities of ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Quanhai, Kawamura, Kiyoko, Yang, Shan, Okamoto, Shinya, Kobayashi, Hiroshi, Tada, Yuji, Sekine, Ikuo, Takiguchi, Yuichi, Shingyouji, Masato, Tatsumi, Koichiro, Shimada, Hideaki, Hiroshima, Kenzo, Tagawa, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745385/ https://www.ncbi.nlm.nih.gov/pubmed/23977343 http://dx.doi.org/10.1371/journal.pone.0072709

Ejemplares similares

Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels
por: Okamoto, Shinya, et al.
Publicado: (2013)

Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma
por: Jiang, Yuanyuan, et al.
Publicado: (2016)

Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured
por: Suzuki, Takeo, et al.
Publicado: (2014)

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
por: Tada, Yuji, et al.
Publicado: (2016)

A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects
por: Tagawa, Masatoshi, et al.
Publicado: (2011)

Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression
por: Yang, Shan, et al.
Publicado: (2015)

A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
por: Tada, Yuji, et al.
Publicado: (2015)

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
por: Shimazu, Kengo, et al.
Publicado: (2017)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
por: Qin, Yiyang, et al.
Publicado: (2017)

A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine
por: Tada, Yuji, et al.
Publicado: (2013)

Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes
por: Yamauchi, Suguru, et al.
Publicado: (2017)

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions
por: Okamoto, S, et al.
Publicado: (2014)

Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen
por: Zhong, Boya, et al.
Publicado: (2015)

An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced
por: Morinaga, Takao, et al.
Publicado: (2017)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Diffuse pleural thickening and thoracic contraction: An indistinguishable case from malignant pleural mesothelioma
por: Tada, Yuji, et al.
Publicado: (2020)

AMPK activation induced in pemetrexed‐treated cells is associated with development of drug resistance independently of target enzyme expression
por: Qin, Yiyang, et al.
Publicado: (2019)

Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China
por: Ma, Guangyu, et al.
Publicado: (2009)

An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
por: Nguyen, Thao Thi Thanh, et al.
Publicado: (2021)

Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma
por: Ma, G, et al.
Publicado: (2010)

Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity
por: Chai, Kuan, et al.
Publicado: (2018)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
por: Kim, Jung Sun, et al.
Publicado: (2017)

Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
por: Bijelic, Lana, et al.
Publicado: (2012)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
por: KURIMOTO, RYOTA, et al.
Publicado: (2016)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
por: Bearz, Alessandra, et al.
Publicado: (2012)

Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
por: Biersack, Bernhard
Publicado: (2018)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma
por: Youk, Jeonghwan, et al.
Publicado: (2017)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
por: Røe, Oluf Dimitri, et al.
Publicado: (2012)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
por: Oien, Derek B., et al.
Publicado: (2018)

Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma
por: Satoh, Toshiyuki, et al.
Publicado: (2017)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kiekb1cd8i61r8hrn2vlqqp5lc